Full Text Journal Articles by
Author Taizo Hijioka

Advertisement

Find full text journal articles








Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.

Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Hideki Hagiwara, Yasuharu Imai, Naoki Hiramatsu, Shinji Tamura, Keiji Yamamoto, Masahide Oshita, Kazuyoshi Ohkawa, Taizo Hijioka, Hiroyuki Fukui, Toshifumi Ito, Yoshinori Doi, Yukinori Yamada, Takayuki Yakushijin, Yuichi Yoshida, Tomohide Tatsumi, Tetsuo Takehara, ,

<h4>Background</h4>Several factors associated with hepatocellular carcinoma (HCC) occurrence after sustained virological response (SVR) in patients with hepatitis C have been reported. However, few validation studies have been performed in the era of direct-acting anti-virals (DAAs).<h4>Aims</h4>To develop a prediction model for HCC occurrence after DAA-mediated SVR and validate its usefulness.<h4>Methods</h4>We analysed ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment.

Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Ryoko Yamada, Kazuyoshi Ohkawa, Naoki Hiramatsu, Hideki Hagiwara, Masahide Oshita, Taizo Hijioka, Shinji Tamura, Yasuharu Imai, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Several studies have recently reported that hepatocellular carcinoma (HCC) occurrence does not differ between hepatitis C virus patients receiving interferon (IFN)-based and IFN-free treatments considering the patients' backgrounds. However, liver fibrosis was not directly considered in these studies.<h4>Methods</h4>In total, 3972 patients without a history of HCC who started IFN-based or IFN-free ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(3):313-320]

Cited: 0 times

View full text PDF listing >>



Advertisement

Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients.

Ayako Urabe, Ryotaro Sakamori, Yuki Tahata, Ryoko Yamada, Yasuharu Imai, Hideki Hagiwara, Shinji Tamura, Hiroyuki Fukui, Yukinori Yamada, Akira Kaneko, Taizo Hijioka, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Sofosbuvir (SOF) and ribavirin (RBV) combination therapy has improved the sustained virologic response (SVR) rate and shortened the treatment duration for patients with chronic hepatitis C virus (HCV) genotype 2 infection. Ribavirin-induced hemolytic anemia is one of the most troublesome side-effects of SOF/RBV therapy; however, factors associated with this condition ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(8):853-859]

Cited: 0 times

View full text PDF listing >>



Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.

Ryoko Yamada, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Naoki Morishita, Takahiro Kodama, Hayato Hikita, Ryotaro Sakamori, Takayuki Yakushijin, Akira Yamada, Hideki Hagiwara, Eiji Mita, Masahide Oshita, Toshifumi Itoh, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Atsuo Inoue, Yasuharu Imai, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment α-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(5):570-578]

Cited: 7 times

View full text PDF listing >>



Lack of association between the CARD10 rs6000782 polymorphism and type 1 autoimmune hepatitis in a Japanese population.

Kiyoshi Migita, Yuka Jiuchi, Hiroshi Furukawa, Minoru Nakamura, Atsumasa Komori, Michio Yasunami, Hideko Kozuru, Seigo Abiru, Kazumi Yamasaki, Shinya Nagaoka, Satoru Hashimoto, Shigemune Bekki, Kaname Yoshizawa, Masaaki Shimada, Hiroshi Kouno, Hiroshi Kamitsukasa, Tatsuji Komatsu, Taizo Hijioka, Makoto Nakamuta, Atsushi Naganuma, Haruhiro Yamashita, Hideo Nishimura, Hajime Ohta, Yoko Nakamura, Keisuke Ario, Yukio Oohara, Kazuhiro Sugi, Minoru Tomizawa, Takeaki Sato, Hironao Takahashi, Toyokichi Muro, Fujio Makita, Eiji Mita, Hironori Sakai, Hiroshi Yatsuhashi,

<h4>Background</h4>Previous genome-wide association studies have evaluated the impact of common genetic variants and identified several non-HLA risk loci associated with autoimmune liver diseases. More recent genome-wide association studies and replication analyses reported an association between variants of the CARD10 polymorphism rs6000782 and risk of type 1 autoimmune hepatitis (AIH). In ... Read more >>

BMC Res Notes (BMC research notes)
[2015, 8:777]

Cited: 6 times

View full text PDF listing >>



The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.

Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Naoki Morishita, Naoki Harada, Ryoko Yamada, Takayuki Yakushijin, Eiji Mita, Hideki Hagiwara, Yukinori Yamada, Toshifumi Ito, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Keiko Irishio, Michio Kato, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>Hyperbilirubinemia, mild or moderate, is a commonly observed laboratory abnormality in chronic hepatitis C patients treated with simeprevir with pegylated interferon (Peg-IFN) plus ribavirin. In this prospective, multicenter study, we aimed to investigate the clinical features and factors associated with bilirubin increases during the therapy.<h4>Methods</h4>A total of 192 patients with ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2016, 51(3):252-259]

Cited: 7 times

View full text PDF listing >>



Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Masanori Miyazaki, Akira Yamada, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Akinori Kasahara, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara, ,

<h4>Background & aims</h4>In patients with chronic hepatitis C virus (HCV) infection, lack of sustained virologic response (SVR) 24 weeks after the end of interferon therapy is a significant risk factor for hepatocellular carcinoma (HCC). Although many pretreatment factors are known to affect HCC incidence, less is known about post-treatment factors-many ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2014, 12(7):1186-1195]

Cited: 47 times

View full text PDF listing >>



Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Masanori Miyazaki, Sadaharu Iio, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>HCV kinetics during treatment demonstrated strong association with the antiviral outcome of patients treated with pegylated interferon (Peg-IFN) plus ribavirin. However, the relationship between HCV kinetics and pre-treatment factors remains unclear.<h4>Methods</h4>Of 547 patients with HCV genotype 1 treated with Peg-IFN alfa-2b plus ribavirin, 401 completed the response-guided therapy and were ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2014, 49(4):737-747]

Cited: 3 times

View full text PDF listing >>



Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.

Tsugiko Oze, Naoki Hiramatsu, Changho Song, Takayuki Yakushijin, Sadaharu Iio, Yoshinobu Doi, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Masanori Miyazaki, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>The timing to the first undetectable hepatitis C virus (HCV) RNA level is strongly associated with sustained virologic response in pegylated interferon (Peg-IFN) plus ribavirin combination therapy for patients with chronic hepatitis C (CH-C) with genotype 1. This study was conducted to clarify the impact of drug exposure to Peg-IFN ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2012, 47(3):334-342]

Cited: 2 times

View full text PDF listing >>



Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study).

Kiyoshi Migita, Yukio Watanabe, Yuka Jiuchi, Yoko Nakamura, Akira Saito, Michiyasu Yagura, Hajime Ohta, Masaaki Shimada, Eiji Mita, Taizo Hijioka, Haruhiro Yamashita, Eiichi Takezaki, Toyokichi Muro, Hironori Sakai, Makoto Nakamuta, Seigo Abiru, Atsumasa Komori, Masahiro Ito, Hiroshi Yatsuhashi, Minoru Nakamura, Hiromi Ishibashi, ,

BACKGROUND/AIMS: Although the outcome of autoimmune hepatitis (AIH) is generally good, the natural course and likelihood of progression to cirrhosis or hepatocellular carcinoma (HCC) remain undefined, and may vary by region and population structure. Our aims were to evaluate risk factors that contribute to poor outcome and particularly development of ... Read more >>

Liver Int (Liver international : official journal of the International Association for the Study of the Liver)
[2012, 32(5):837-844]

Cited: 34 times

View full text PDF listing >>



Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Kaytayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi,

<h4>Background & aims</h4>This study investigated the efficacy and adverse effects of pegylated interferon (Peg-IFN) plus ribavirin therapy in aged patients with chronic hepatitis C (CH-C).<h4>Methods</h4>A total of 1040 naïve patients with CH-C (genotype 1, n=759; genotype 2, n=281), of whom 240 (23%) over 65 years old (y.o.), were treated with ... Read more >>

J Hepatol (Journal of hepatology)
[2011, 54(4):604-611]

Cited: 30 times

View full text PDF listing >>



The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Akira Kaneko, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Toshihiko Nagase, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Eijiro Hayashi, Yasuharu Imai, Michio Kato, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Hisashi Ishida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi,

<h4>Background</h4>Which patients with hepatitis C virus (HCV) genotype 1 can benefit from extended treatment with pegylated interferon (Peg-IFN) plus ribavirin is unknown, although the overall sustained virologic response (SVR) rate has been shown to improve in patients with a late virologic response (LVR), defined as detectable serum HCV RNA at ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2011, 46(7):944-952]

Cited: 10 times

View full text PDF listing >>



Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Hiroyuki Fukui, Taizo Hijioka, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Atsushi Hosui, Takuya Miyagi, Hisashi Ishida, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi,

<h4>Background</h4>It is still not known which patients with chronic hepatitis C who failed to respond to previous pegylated interferon (Peg-IFN) plus ribavirin therapy can benefit from re-treatment.<h4>Methods</h4>Seventy-four patients (HCV genotype 1, n = 56, genotype 2, n = 18) were re-treated with Peg-IFN plus ribavirin.<h4>Results</h4>On re-treatment, the sustained virologic response ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2011, 46(8):1031-1037]

Cited: 9 times

View full text PDF listing >>



[An imported Japanese case of cyclosporiasis].

Yuko Sakakibara, Atsuo Takigawa, Yuri Kawabata, Tamaki Hirotani, Kaori Mukai, Kengo Matsumoto, Fumihiko Nakanishi, Yoshio Tanaka, Eiji Masuda, Taizo Hijioka,

A 42-year-old Japanese woman, who resided in Indonesia suffered from watery diarrhea. As soon as she returned to Japan, she had a medical examination at our hospital. Oocysts of Cyclospora cayetanensis were isolated from her stool on the 14th day. Treatment with 1.6g/day sulfamethoxazole/trimethoprim combination for 1 week was effective. ... Read more >>

Nihon Shokakibyo Gakkai Zasshi (Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology)
[2010, 107(8):1290-1295]

Cited: 0 times

View full text PDF listing >>



[Investigation of simplified international diagnostic criteria for autoimmune hepatitis].

Akira Kaneko, Mitsuhiko Kubo, Ryoko Yamada, Tomoki Tanimura, Daisuke Yamaguchi, Moritoshi Yamamoto, Nobuyuki Tatsumi, Akihiro Nakama, Eiji Mita, Michio Kato, Taizo Hijioka, Masahide Oshita, Toshifumi Ito, Kazuho Imanaka, Kazuhiro Katayama, Masako Sato, Harumasa Yoshihara, Kazuo Kiriyama, Yasuharu Imai, Takeshi Kashihara, Hiroyuki Fukui, Kunio Suzuki, Shio Miyoshi, Akira Yamada, Takayuki Yakushijin, Kiyoshi Mochizuki, Naoki Hiramatsu, Tetsuo Takehara, Norio Hayashi,

The simplified international diagnostic criteria for autoimmune hepatitis (AIH), re-revised by the International AIH Group in 2008, were investigated in 114 patients with AIH from 15 centers in Japan. While applying of the criteria, we had to pay attention to anti-nuclear antibody measurement methods, and liver histology scoring. Definite and ... Read more >>

Nihon Shokakibyo Gakkai Zasshi (Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology)
[2010, 107(5):732-742]

Cited: 1 time

View full text PDF listing >>



Evaluation of risk factors for the development of cirrhosis in autoimmune hepatitis: Japanese NHO-AIH prospective study.

Kiyoshi Migita, Yukio Watanabe, Yuka Jiuchi, Yoko Nakamura, Akira Saito, Michiyasu Yagura, Hideo Morimoto, Masaaki Shimada, Eiji Mita, Taizo Hijioka, Haruhiro Yamashita, Eiichi Takezaki, Toyokichi Muro, Hironori Sakai, Makoto Nakamuta, Seigo Abiru, Koji Yano, Atsumasa Komori, Hiroshi Yatsuhashi, Minoru Nakamura, Hiromi Ishibashi,

Autoimmune hepatitis (AIH) is a chronic and progressive liver disease characterized by histological interface hepatitis and circulating autoantibodies. Our aims were to evaluate risk factors that contribute to the outcome and, particularly, the development of liver cirrhosis in a prospective multicenter cohort study of AIH. One hundred and seventy-four patients ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2011, 46 Suppl 1:56-62]

Cited: 9 times

View full text PDF listing >>



Dynamic epidemiology of acute viral hepatitis in Japan.

Koji Yano, Yoko Tamada, Hiroshi Yatsuhashi, Atsumasa Komori, Seigo Abiru, Kiyoaki Ito, Naohiko Masaki, Masashi Mizokami, Hiromi Ishibashi, ,

The epidemiology of acute viral hepatitis (AVH) is dynamic and affected by many factors including hygiene, socioeconomic status and vaccination coverage. A total of 4,302 cases of AVH were sequentially enrolled in this nationwide study between 1980 and 2008. Of the cases of AVH, acute hepatitis A (AHA) accounted for ... Read more >>

Intervirology (Intervirology)
[2010, 53(1):70-75]

Cited: 26 times

View full text PDF listing >>



Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis.

Mika Kurokawa, Naoki Hiramatsu, Tsugiko Oze, Kiyoshi Mochizuki, Takayuki Yakushijin, Nao Kurashige, Yuko Inoue, Takumi Igura, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Shinichi Kiso, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Norio Hayashi,

<h4>Aim</h4>The objective of this study was to elucidate the long-term effects of interferon (IFN)alpha-2b plus ribavirin combination therapy and to clarify whether this therapy can reduce the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C.<h4>Methods</h4>A total of 403 patients infected with hepatitis C virus (HCV) were enrolled ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2009, 39(5):432-438]

Cited: 24 times

View full text PDF listing >>



Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003.

Hideo Tanaka, Yasuharu Imai, Naoki Hiramatsu, Yuri Ito, Kazuho Imanaka, Masahide Oshita, Taizo Hijioka, Kazuhiro Katayama, Iwao Yabuuchi, Harumasa Yoshihara, Atsuo Inoue, Michio Kato, Tetsuo Takehara, Shinji Tamura, Akinori Kasahara, Norio Hayashi, Hideaki Tsukuma,

<h4>Background</h4>Japan has the highest incidence rate of primary liver cancer attributed to chronic hepatitis C virus (HCV) infection among developed countries. Molecular clock analysis of HCV sequences revealed that the spread of HCV took place earlier in Japan than in other countries. This might influence recent temporal trends in hepatocellular ... Read more >>

Ann Intern Med (Annals of internal medicine)
[2008, 148(11):820-826]

Cited: 65 times

View full text PDF listing >>



Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine.

Nao Kurashige, Naoki Hiramatsu, Kazuyoshi Ohkawa, Tsugiko Oze, Yuko Inoue, Mika Kurokawa, Takayuki Yakushijin, Takumi Igura, Shinichi Kiso, Tatsuya Kanto, Tetsuo Takehara, Shinji Tamura, Akinori Kasahara, Masahide Oshita, Taizo Hijioka, Kazuhiro Katayama, Harumasa Yoshihara, Eijirou Hayashi, Yasuharu Imai, Michio Kato, Norio Hayashi,

<h4>Aim</h4>Lamivudine (LAM) has been widely used to treat chronic hepatitis B (CHB) patients, but the emergence of a LAM-resistant virus greatly limits its therapeutic efficacy. In this study, we tried to identify factors affecting the emergence of a LAM-resistant virus in CHB patients treated with LAM.<h4>Methods</h4>The subjects were 190 CHB ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2008, 38(5):450-456]

Cited: 5 times

View full text PDF listing >>



Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers.

Miyako Nakano, Tsutomu Nakagawa, Toshifumi Ito, Takatoshi Kitada, Taizo Hijioka, Akinori Kasahara, Michiko Tajiri, Yoshinao Wada, Naoyuki Taniguchi, Eiji Miyoshi,

It was found in our previous studies that the concentration of fucosylated haptoglobin had increased in the sera of patients with pancreatic cancer (PC) compared to those of other types of cancer and normal controls. Haptoglobin, an acute phase protein, has four potential N-glycosylation sites, although it remains unknown which ... Read more >>

Int J Cancer (International journal of cancer)
[2008, 122(10):2301-2309]

Cited: 72 times

View full text PDF listing >>



Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

Tsugiko Oze, Naoki Hiramatsu, Nao Kurashige, Natsuko Tsuda, Takayuki Yakushijin, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Michio Kato, Harumasa Yoshihara, Kazuhiro Katayama, Shinji Kubota, Taizo Hijioka, Kazunobu Ishibashi, Masahide Oshita, Hideki Hagiwara, Yoshimichi Haruna, Eiji Mita, Shinji Tamura, Norio Hayashi,

<h4>Background</h4>The aim of this study was to examine the factors correlated with the progression of ribavirin-induced hemolytic anemia in patients with chronic hepatitis C treated by interferon and ribavirin combination therapy.<h4>Methods</h4>This study was conducted on 505 patients by the Osaka Liver Disease Study Group. A decline of hemoglobin (Hb) concentration ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2006, 41(9):862-872]

Cited: 14 times

View full text PDF listing >>



Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?

Naoki Hiramatsu, Tsugiko Oze, Natsuko Tsuda, Nao Kurashige, Keisuke Koga, Takashi Toyama, Masakazu Yasumaru, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Michio Kato, Harumasa Yoshihara, Kazuhiro Katayama, Taizo Hijioka, Hideki Hagiwara, Shinji Kubota, Masahide Oshita, Yoshimichi Haruna, Eiji Mita, Kunio Suzuki, Kazunobu Ishibashi, Norio Hayashi,

<h4>Unlabelled</h4>The aim of this study was to investigate the efficacy and safety of combination therapy of interferon and ribavirin for aged patients with chronic hepatitis C.<h4>Methods</h4>This study was conducted at Osaka University Hospital and institutions participating in the Osaka Liver Disease Study Group on 329 patients with chronic hepatitis C ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2006, 35(3):185-189]

Cited: 26 times

View full text PDF listing >>



The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan.

Naoki Hiramatsu, Akinori Kasahara, Fumihiko Nakanishi, Takashi Toyama, Masahiko Tsujii, Shingo Tsuji, Tatsuya Kanto, Tetsuo Takehara, Michio Kato, Harumasa Yoshihara, Masafumi Naito, Kazuhiro Katayama, Taizo Hijioka, Hideki Hagiwara, Shinji Kubota, Masahide Oshita, Haruya Meren, Manabu Masuzawa, Yoshimichi Haruna, Eiji Mita, Kunio Suzuki, Norio Hayashi,

One hundred seventy-one patients with chronic hepatitis C were included in this study (genotype1 and high viral loads (1H), [Formula: see text]; non-1H, [Formula: see text]; N.D., [Formula: see text] ). The combination therapy of interferon and ribavirin for 24 weeks with an additional 24 weeks of interferon monotherapy (48-week ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2004, 29(3):142-147]

Cited: 4 times

View full text PDF listing >>





Advertisement


Disclaimer

1.7913 s